MedTrace Logo

MMF and Calcineurin Inhibitor Withdrawal in CAN

NCT00204230 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2005-09-20

No results posted yet for this study

Summary

Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in patients with histologically proven chronic allograft nephropathy Indication: change in immunosuppressive treatment of chronic allograft nephropathy (CAN)after renal transplantation Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure/ metabolic parameters and structural vessel wall changes

Primary Target:effects of CNI withdrawal and MMF on renal function: stabilisation and/or improvement Secondary Targets: Incidence of adverse events Evaluation of the calcineurin inhibitor free MMF treatment effects on blood pressure, lipids, glucose metabolism and on structural and functional vesselwallchanges Method:open prospective, randomized two-tailed, monocentric study

Conditions

  • Immunosuppressive Agents
  • Kidney Failure, Chronic
  • Kidney Transplantation

Interventions

DRUG

mycophenolate mofetil (drug)

Sponsors & Collaborators

Principal Investigators

  • Barbara M Suwelack, PhD · University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2002-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00204230 on ClinicalTrials.gov